

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2019 (19.12.2019)



(10) International Publication Number
WO 2019/238882 A1

- (51) **International Patent Classification:**
C07K 16/24 (2006.01) *A61K 39/00* (2006.01)
A61P 35/00 (2006.01)
- (21) **International Application Number:**
PCT/EP2019/065598
- (22) **International Filing Date:**
13 June 2019 (13.06.2019)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
1809699.0 13 June 2018 (13.06.2018) GB
- (71) **Applicants:** SINGAPORE HEALTH SERVICES PTE. LTD. [SG/SG]; 31 Third Hospital Avenue, #03-03 Bowyer Block C, Singapore 168753 (SG). NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). ENLEOFEN BIO PTE. LTD. [SG/SG]; 160 Robinson Road, SBF Center #23-02, Singapore 068914 (SG).
- (71) **Applicant (for LS only):** CLEGG, Richard Ian [GB/GB]; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).
- (72) **Inventors:** COOK, Stuart Alexander; 6 Sunset Square, Clementi Park, Singapore 597304 (SG). SCHAEFER, Sebastian; 76 Shenton Way, 76 Shenton #24-04, Singapore 079119 (SG).
- (74) **Agent:** MEWBURN ELLIS LLP; City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) **Title:** IL-11 ANTIBODIES

Strategy No	Round 1	Round 2	Round 3	biotinylated	No first hits
1	h-IL11	m-IL11	h-IL11	Yes	1
2	h-IL11	h-IL11	h-IL11	Yes	-
3	h-IL11	h-IL11	m-IL11	Yes	-
4	m-IL11	m-IL11	m-IL11	Yes	5
5	m-IL11	h-IL11	m-IL11	Yes	-
6	m-IL11	h-IL11	h-IL11	Yes	-
7	h-IL11	h-IL11	h-IL11	No	11
8	h-IL11	m-IL11	h-IL11	No	14
9	h-IL11	m-IL11	h-IL11	Round 2	17
10	h-IL11	h-IL11	m-IL11	No	19
11	h-IL11	h-IL11	m-IL11	Round 3	5
12	m-IL11	h-IL11	m-IL11	Round 3	10
13	m-IL11	m-IL11	h-IL11	Round 1, 2	6
14	m-IL11	m-IL11	m-IL11	No	36
15	m-IL11	h-IL11	m-IL11	No	15
16	m-IL11	m-IL11	h-IL11	No	36

Figure 1

(57) **Abstract:** Provided a re antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same.

[Continued on next page]



WO 2019/238882 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*